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Background: There have been sporadic reports about synchronous as well as metachronous gastric
adenocarcinoma and primary gastric lymphoma. Many reports have dealt with metachronous gastric
adenocarcinoma in mucosa-associated lymphoid tissue lymphoma of stomach. But to our knowledge, there
have been no reports that document the increased incidence of metachronous gastric adenocarcinoma in
patients with gastric diffuse large B-cell lymphoma. This retrospective study was conducted to estimate the
incidence of metachronous gastric adenocarcinoma after primary gastric lymphoma treatment, especially in
diffuse large B-cell lymphoma.
Methods: The retrospective cohort study of 139 primary gastric lymphoma patients treated with radiotherapy
at our hospital. Mean observation period was 61.5 months (range: 3.7-124.6 months). Patients profile, characteristics
of primary gastric lymphoma and metachronous gastric adenocarcinoma were retrieved from medical records. The
risk of metachronous gastric adenocarcinoma was compared with the risk of gastric adenocarcinoma in Japanese
population.
Results: There were 10 (7.2%) metachronous gastric adenocarcinoma patients after treatment of primary
gastric lymphomas. It was quite high risk compared with the risk of gastric carcinoma in Japanese population of
54.7/100,000. Seven patients of 10 were diffuse large B-cell lymphoma and other 3 patients were mixed type of
diffuse large B-cell lymphoma and mucosa associated lymphoid tissue lymphoma. Four patients of 10
metachronous gastric adenocarcinomas were signet-ring cell carcinoma and two patients died of gastric
adenocarcinoma. Metachronous gastric adenocarcinoma may have a more malignant potential than sporadic
gastric adenocarcinoma. Old age, Helicobacter pylori infection and gastric mucosal change of chronic gastritis
and intestinal metaplasia were possible risk factors for metachronous gastric adenocarcinoma.
Conclusion: There was an increased risk of gastric adenocarcinoma after treatment of primary gastric lymphoma,
especially of diffuse large B-cell lymphoma.
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There have been sporadic reports about synchronous as
well as metachronous gastric adenocarcinoma (GA) and
primary gastric lymphoma (PGL) [1-16]. Regarding syn-
chronous GA and PGL, Ishihama et al. reported that GA
was seen synchronously in 3.3% of PGL patients (4/121
patients) [8]. Concerning the metachronous GA and
PGL, the largest study is that of Capelle LG et al. which
reported that metachronous GA risk was six times
higher in the patients with gastric mucosa associated
lymphoid tissue (MALT) lymphoma than in the Dutch
general population [16]. Many reports have dealt with
metachronous GA in MALT lymphoma of stomach. But
to our knowledge, there have been no reports that docu-
ment the increased incidence of metachronous GA in
patients with gastric diffuse large B-cell lymphoma
(DLBCL). This retrospective study was conducted to es-
timate the incidence of metachronous GA after PGL
treatment, especially in DLBCL.
Methods
The radiation oncology department database from 2000
to 2010 was searched for PGL patients who underwentTable 1 Patient’s characteristic and PGL treatment
DLBCL
N 139 83
Age Median 62 ( range: 19–85) Median 63 ( range:
Sex (M : F) 71 : 68 44 : 39
Stage I 94 I
(Lugano) II 40 II
IV 5 IV
Treatment RT 50 RT
CT+RT 89 CT+RT
Rituximab R+ 40 R+
R- 99 R-
RT dose 40 Gy/20fr
40 Gy≧ 89 40.5 Gy/27fr
40 Gy< 50 44 Gy/22fr
30 Gy/15fr
Observation length mean 61.5 months mean 62.7 mont
(range) (3.7–124.6) (7.1–124.6)
5 year OS 92.0% 89.6%
PGL: primary gastric lymphoma.
DLBCL: diffuse large B-cell lymphoma.
MALT: mucosa-associated lymphoid tissue.
ATL: adult T-cell lymphoma.
FL: follicular lymphoma.




R: rituximab.radiotherapy. Patient’s profiles at the time of PGL diag-
nosis (age, sex, lymphoma histology, stage, treatment
and outcome) were retrieved retrospectively. After treat-
ment of PGL, patients underwent regular follow-ups
including endoscopic examinations and CT scannings.
The date of GA diagnosis, interval between PGL and
GA, stage of GA, treatment of GA and outcome were
also investigated. One of the authors, an experienced
gastrointestinal pathologist, reviewed the biopsy slides at
the time of PGL and GA diagnosis and the presence of
atrophic gastritis and intestinal metaplasia was diagnosed.
In the 10 patients with metachronous GA after PGL, the
presence of Helicobacter pylori (HP) infection was diag-
nosed retrospectively by pathology findings of the biopsy
specimens or by results of the various laboratory tests.
Estimated risk of GA after PGL was calculated in com-
parison to the incidence of GA in Japanese population.
Our institutional review board (National Cancer Center
Institutional Review Board) approved this study.
Results
There were 139 patients with PGL (MALT lymphoma in
51 patients, DLBCL in 83, peripheral T-cell lymphomaMALT lymphoma Others
51 5 (ATL 2, FL 2, PTCL 1)
20–85) Median 56 ( range: 19–76) Median 64 ( range: 53–72)
25 : 26 2 : 3
42 I 48 I 4
37 II 2 II 1
4 IV 1
0 RT 49 RT 1
83 CT+RT 2 CT+RT 4
38 R+ 1 R+ 1
45 R- 50 R- 4
35 30 Gy/15fr 23 40 Gy/20fr 2
45 30 Gy/20fr 24 40.5 Gy/27fr 2
2 36 Gy/18fr 1 36 Gy/18fr 1
1 40 Gy/20fr 1
46 Gy/23fr 2
hs mean 61.0 months mean 46.9 months
(3.7–120.4) (11.5–82.4)
97.7% 75.0%
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follicular lymphoma (FL) in 2). Eighteen patients with
MALT lymphoma were treated by radiation therapy
because of the residual tumors after HP eradication, and
the remaining 33 patients underwent radiation therapy
because they were HP negative. Patient characteristics
are shown in Table 1. Mean observation length was
61.5 months (range: 3.7-124.6 months). All PGLs in theTable 2 Metachronous GA and details
No Age Sex PGLpathology
Lugano
stage
Tx for PGL Interval (months)
from PGL to GA
1 72 F DLBCL II1 CHOP×3 42.6
+
40 Gy/20fr
2 62 M DLBCL I CHOP×3 64.3
+
40.5 Gy/27fr
3 70 M DLBCL II1 CHOP×3 45.9
+
40.5 Gy/27fr
4 68 F DLBCL I CHOP×3 90.8
+
40.5 Gy/27fr
5 70 M DLBCL II1 CHOP×3 16.0
+
40.5 Gy/27fr
6 63 M DLBCL IV R×8-CHOP×8 30.2
+
40.5 Gy/27fr
7 36 M MALT II1 R×8-CHOP×3 42.1
+ +
DLBCL 40 G y/20fr
8 63 M DLBCL II1 R×8-CHOP×6 73.7
+
40.5 Gy/27fr
9 66 F MALT II1 CHOP×3 17.5
+ +
DLBCL 40.5 Gy/27fr
10 73 F MALT I CHOP×4 7.9
+ +
DLBCL 40.5 Gy/27fr









CHOP: cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone.current study were treated by radiotherapy and almost
all patients except MALT were treated with chemo-
radiotherapy. There were seen 10 patients with GA
developed after treatment of PGL. No synchronous GA
was found in this study. Tables 2 and 3 show the details
of metachronous GA. The mean latent period between
PGL and GA was 43.1 months (range: 7.9-90.8 months)
(Figure 1). The histological types of GA were wellGA
pathology
Stage
for GA Tx for GA Outcome
sig m distal gastrectomy Alive for 3.7 m after GA
W/D AC m ESD Alive for 47.7 m after GA
W to M/D AC m ESD Alive for 71.6 m after GA
W/D AC m ESD Alive for 31.8 m after GA
W/D AC sm EMR→partial
gastrectomy
Dead for 36.9 m after GA
W to P/D AC se total gastrectomy Dead for 12.0 m after GA
sig m partial gastrectomy Alive for 20.6 m after GA
sig m EMR Alive for 16.6 m after GA
sig m EMR Alive for 69.3 m after GA
W/D AC m EMR Alive for 70.2 m after GA














1 atorophic + atorophic + possible
2 atorophic + atorophic + +
3 atorophic + atorophic + possible
4 atorophic + atorophic + +
5 atorophic - atorophic + +
6 atorophic - atorophic + possible
7 normal - atorophic + +
8 atorophic - atorophic + +
9 atorophic + atorophic + possible
10 atorophic + atorophic + possible
HP infection possible means background gastric mucosal changes suggesting
HP infection.










M 71 6 (8%)
0.4 1.47 0.40–5.48
F 68 4 (6%)
Age
60≦ 64 1 (2%)
0.02※ 8.59 1.06–69.78
60> 75 9 (12%)
Histology of
Lymphoma




HP positive 22 5 (23%)
0.007※ - -
HP negative 34 0
Chemotherapy
Yes 88 10 (11%)
0.009※ - -
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http://www.biomedcentral.com/1471-2407/13/499differentiated adenocarcinoma in 4 patients, well to
moderate differentiated adenocarcinoma in one, well to
poorly differentiated adenocarcinoma in one, and signet-
ring cell carcinoma in 4. In 9 patients, GA was classified
as stage I and the remaining one was diagnosed as stage
II. About the lymphoma histology, seven patients were
classified as DLBCL and the remaining 3 showed a
mixture of DLBCL and MALT lymphoma. For the GA,
endoscopic resection was performed in 6 patients with
no relapses. Four patients underwent surgery with re-
lapses seen in 2 patients. Both of them succumbed to
distant metastasis 9 and 37 months after surgery despite
chemotherapy. Two- and 5-year overall survivals of GA
were 90.0% and 75.0%. The 5-year overall survivals of
DLBCL and MALT lymphoma were 89.6% and 97.7%
respectively. Eight of the 83 DLBCL patients died, of
which 5 were from non-lymphoma causes. Two of the 5
died from metachronous GA.Figure 1 Incidence of GA/ all PGL and DLBCL. GA: gastric
adenocarcinoma, PGL: primary gastric lymphoma, DLBCL: diffuse
large B-cell lymphoma.In the 10 patients with metachronous GA after PGL,
mucosal findings at the time of PGL showed atrophic
gastritis in 9 patients and intestinal metaplasia in 6. In
contrast, the mucosa at the time of GA diagnosis
showed atrophic gastritis and intestinal metaplasia in all
10 patients. Of 10 patients who developed GA after
PGL, 5 had HP infection, and the remaining 5 patients
had no information of HP infection but the background
gastric mucosal changes of atrophic gastritis and intes-
tinal metaplasia suggested possible presence of HP infec-
tion (Table 3).
Table 4 compared factors between the whole patients
and the patients with metachronous GA. The incidence
of metachronous GA was higher in the patients with ageNo 51 0
Rituximab
Yes 40 3 (8%)
0.59 1.07 0.26–4.34
No 99 7 (7%)
Stage
Stage I 93 3 (3%)
0.02※ 5.38 1.32–21.92
Stage II-IV 46 7 (15%)
Chronic Gastritis
Yes 65 9 (14%)
0.26 3.05 0.36–25.71
No 20 1 (5%)
Intestinal
Metaplasia
Yes 29 6 (21%)
0.07 3.39 0.87–13.17
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therapy and stage II-IV with a statistical significance and
the presence of intestinal metaplasia of gastric mucosa
with a marginal significance (p=0.07).
The risk of metachronous GA after PGL was 10/139
(=7.2%). If confined to DLBCL, the risk was 10/83
(=12.0%) (Figure 1). The risk of GA in Japanese popula-
tion is about 54.7/100,000 [17]. The relative risk was 131
(95% confidence interval: 68–251). If confined to DLBCL,
the relative risk was 219 (95% confidence interval:
116–415).
Discussion
There were 10 patients developing metachronous GA
after treatment of PGL. The risk of metachronous GA
was higher in the patients with age over 60 years,
DLBCL, HP infection, use of chemotherapy, Stage II-IV
of PGL. In this study, MALT lymphomas were treated
by radiation therapy after HP eradication as described in
European Gastro-Intestinal Lymphoma Study (EGILS)
group consensus report [18]. HP eradication and HP
negative may explain that MALT lymphomas in this
study showed no increased risk of metachronous GA.
Increased risk of GA in Stage II-IV and patients treated
with chemotherapy can be explained by the fact that
only the patients with DLBCL showed advanced stages
and treated by chemotherapy. Multivariate analysis to
estimate factors for metachronous GA showed no statis-
tical significance due to small number.
HP infection is well known in causing atrophic gastri-
tis and intestinal metaplasia which might lead to GA.
Not only the ongoing HP infection, but also radiation
and chemotherapy could have contributed the mucosal
change.
Old patients with primary gastric diffuse large B-cell
lymphoma (PGDLBCL) who remains HP-infection posi-
tive and have mucosal change of atrophic gastritis and
intestinal metaplasia should be followed up cautiously
early to find metachronous GA and eradication of HP
infection should be considered.
The increased risk of GA after PGL might be possibly
explained by 2 theories. One is that damages to gastric
mucosa by HP infection, chemotherapy, or radiotherapy
increase GA risk [19-21], and the other is that GA
remained undetected at the time of PGL because GA
was so small [22-24]. Risk of treatment-related solid
cancer increases more than 5 years after the primary
treatment. The interval of GA and PGL was within
5 years in 7 patients. These patients with short interval
may have undetected small GA at the time of PGL and
the patients with longer interval could be caused by con-
tinuing HP infection and/or treatment.
To our knowledge, this is the first report which has
large number of PGL and longtime follow-up and showsthe high risk of GA after treatment of PGL, especially in
DLBCL.
Regarding the nature of GA after PGL, cancerous
infiltration was only up to mucosal layer in 8 patients.
This early detection was due to the short intervals
between endoscopic examinations for PGL follow-ups.
However, 4 of 10 patients had signet-ring cell carcinomas
that had a more aggressive behavior than differentiated
adenocarcinoma. Additionally, 2 patients with submucal
and serosal infiltrations succumbed to distant metastasis
after gastrectomy with 2 year and 5 year overall survival of
90.0% and 75.0%, respectively. GA after PGL may have
more malignant potential than sporadic GA.Conclusion
There were 10 patients of metachronous GA after PGL
and the risk of metachronous GA after PGDLBCL was
10/83(=12.0%). GA after PGL may have more malignant
potential than sporadic GA. Eradication of HP infection
should be considered in PGL to reduce the risk of GA.
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